U.S. Markets open in 5 hrs 7 mins
  • S&P Futures

    4,261.25
    +6.50 (+0.15%)
     
  • Dow Futures

    34,401.00
    +20.00 (+0.06%)
     
  • Nasdaq Futures

    14,148.00
    +23.25 (+0.16%)
     
  • Russell 2000 Futures

    2,324.70
    +1.10 (+0.05%)
     
  • Crude Oil

    71.11
    +0.23 (+0.32%)
     
  • Gold

    1,865.70
    -0.20 (-0.01%)
     
  • Silver

    27.76
    -0.28 (-1.00%)
     
  • EUR/USD

    1.2145
    +0.0022 (+0.1822%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • Vix

    16.38
    +0.73 (+4.66%)
     
  • GBP/USD

    1.4109
    +0.0002 (+0.0113%)
     
  • USD/JPY

    110.0860
    +0.0250 (+0.0227%)
     
  • BTC-USD

    40,409.44
    +338.79 (+0.85%)
     
  • CMC Crypto 200

    1,015.36
    +46.52 (+4.80%)
     
  • FTSE 100

    7,163.06
    +16.38 (+0.23%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Slowing Rates Of Return At LeMaitre Vascular (NASDAQ:LMAT) Leave Little Room For Excitement

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. With that in mind, the ROCE of LeMaitre Vascular (NASDAQ:LMAT) looks decent, right now, so lets see what the trend of returns can tell us.

Understanding Return On Capital Employed (ROCE)

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on LeMaitre Vascular is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.14 = US$32m ÷ (US$247m - US$22m) (Based on the trailing twelve months to March 2021).

Thus, LeMaitre Vascular has an ROCE of 14%. On its own, that's a standard return, however it's much better than the 9.9% generated by the Medical Equipment industry.

View our latest analysis for LeMaitre Vascular

roce
roce

Above you can see how the current ROCE for LeMaitre Vascular compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like to see what analysts are forecasting going forward, you should check out our free report for LeMaitre Vascular.

The Trend Of ROCE

While the current returns on capital are decent, they haven't changed much. Over the past five years, ROCE has remained relatively flat at around 14% and the business has deployed 170% more capital into its operations. Since 14% is a moderate ROCE though, it's good to see a business can continue to reinvest at these decent rates of return. Stable returns in this ballpark can be unexciting, but if they can be maintained over the long run, they often provide nice rewards to shareholders.

In Conclusion...

To sum it up, LeMaitre Vascular has simply been reinvesting capital steadily, at those decent rates of return. On top of that, the stock has rewarded shareholders with a remarkable 246% return to those who've held over the last five years. So while the positive underlying trends may be accounted for by investors, we still think this stock is worth looking into further.

One more thing to note, we've identified 2 warning signs with LeMaitre Vascular and understanding these should be part of your investment process.

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.